Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil concentration in uterine fibroid ablation
NCT06640738Phase 4Not yet recruiting
- Sponsor
- Kaohsiung Medical University
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Orthosteric Ligands
01
Overview
Phase 4, randomised trial of remifentanil in Uterine Fibroids (UF) (2 arms), sponsored by Kaohsiung Medical University. Primary endpoint: Pain scores during uterine fibroid ablation. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
remifentanil
03
Conditions
Uterine Fibroids (UF)
Beyond the preview
Go deeper on NCT06640738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06640738.